Table 4. Outcome results according to XPD and XRCC1–3 polymorphisms in P vs non-P regimens.

	XPD Lys751Gln		XRCC1		XRCC3
	Lys/LysNo. 37	Gln/−No. 60	Gln/GlnNo. 11	Arg/−No. 82	Met/MetNo. 19	Thr/−No. 78
RR (%)
P	47.6	35.7	66.7	34.2	37.5	41.5
Non-P	31.3	21.9	0	29.3	27.3	24.3
OR (95% CI)	1.75 (0.44–7.00)	2.06 (0.65–6.54)	19.41 (0.53–706.26)	1.21 (0.48–3.09)	1.76 (0.24–12.69)	2.05 (0.76–5.51)
P-valuea	0.858		0.143		0.891
Median PFS (mos)
P	6.9 (2.8–12.4)	6.8 (4.3–7.4)	7.5 (0.8–NE)	6.6 (3.9–7.4)	6.8 (0.5–13.8)	6.9 (3.9–7.7)
Non-P	5.0 (3.5–7.5)	5.3 (2.6–8.1)	2.9 (2.0–8.7)	5.1 (3.6–7.5)	4.9 (2.1–8.7)	5.1 (3.4–7.5)
HR (95% CI)	0.83 (0.43–1.62)	0.90 (0.54–1.51)	0.20 (0.05–0.76)	0.98 (0.63–1.52)	0.59 (0.22–1.53)	0.93 (0.59–1.46)
P-valuea	0.842		0.029		0.396
Median OS (mos)
P	9.2 (3.6–18.2)	11.2 (7.1–15.7)	16.6 (0.8–NE)	9.2 (6.4–15.7)	7.9 (1.1–32.5)	12.3 (6.7–15.7)
Non-P	14.9 (5.1–23.3)	11.3 (6.3–23.0)	36.8 (10.3–38.7)	12.5 (6.3–17.0)	15.6 (2.8–28.1)	12.5 (9.7–17.0)
HR (95% CI)	1.11 (0.57–2.17)	1.13 (0.67–1.91)	1.07 (0.28–4.05)	1.11 (0.71–1.73)	1.21 (0.47–3.12)	1.10 (0.70–1.75)
P-valuea	0.975		0.960		0.86

Abbreviations: CI=confidence interval; HR=hazard ratio; mos=months; NE=not estimable; non-P=non-platinum; OR=odds ratio; OS=overall survival; P=platinum; PFS=progression-free survival; RR=response rate; XPD=xeroderma pigmentosum group D; XRCC1=X-ray cross complementing group 1; XRCC3=X-ray cross complementing group 3.

^aTest of interaction.